Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Scla Management LLC

Neither a doctor nor a teaching hospital

Research payments

$1,882,222

543 payments

Through program year 2025, Scla Management LLC is reported as receiving $1,882,222 in research payments, across 543 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $952,383 167
2024 Research $455,399 207
2023 Research $286,081 104
2022 Research $129,500 41
2021 Research $58,859 24

Breakdown

Who paid Research payments · program years 2021–2025
  1. AbbVie, Inc. $468,686 120 payments
  2. Eli Lilly and Company $465,288 9 payments
  3. Averitas Pharma Inc. $324,732 178 payments
  4. Pfizer Inc. $190,610 86 payments
  5. Novartis Pharmaceuticals Corporation $143,303 5 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $83,331 37 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $67,346 48 payments
  8. Kiniksa Pharmaceuticals International, plc $54,928 32 payments
  9. GlaxoSmithKline, LLC. $50,555 8 payments
  10. Kiniksa Pharmaceuticals, Ltd. $17,199 5 payments
Studies the money was for Research payments · program years 2021–2025
  1. An Interventional Phase III Doubleblind Randomized Controlled Parallelgroup Multisite Clinical Trial Evaluating the Efficacy and Safety of Qutenza in Subjects With Postsurgical Neuropathic Pain $324,732 178 payments
  2. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $194,056 5 payments
  3. A Phase 4, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Atopic Dermatitis With Limited Body Surface Area Involvement and High Itch Burden (Adsolve) $154,776 2 payments
  4. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $148,048 35 payments
  5. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $143,303 5 payments
  6. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $116,456 2 payments
  7. A Phase 3 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents 6 to 18 Years of Age $71,087 36 payments
  8. A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis $70,177 5 payments
  9. Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $70,039 27 payments
  10. A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) $67,346 48 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record